Table 1.

Outcomes for direct and indirect comparisons

Outcome	Mean difference (95% CI)
	Direct comparisonsa		Indirect comparisonsb
	TBZ‐placebo	DEU‐placebo	TBZ‐DEU
UHDRS chorea score	−3.5 (−5.2, −1.9)c	−2.5 (−3.7, −1.3)d	−1.00 (−3.04, 1.04)
UHDRS total motor score	−3.3 (−7.0, 0.3)	−4.0 (−6.5, −1.5)d	0.70 (−3.72, 5.12)
Depression scale	0.76 (0.71, 0.81)e	−0.18 (−0.22, −0.14)d	0.94 (0.88, 1.00)d
Epworth Sleepiness Scale	1.8 (0.3, 3.4)e	−0.3 (−1.6, 1.0)d	2.10 (0.08, 4.12)d

CI, confidence interval; TBZ, tetrabenazine; DEU, deutetrabenazine; UHDRS, Unified Huntington's Disease Rating Scale.

^aFor direct comparisons, the values presented are the difference between active treatment and placebo in the mean change in score reported in each individual study. In each case, positive values are in favor of placebo, and negative values are in favor of active treatment.

^bFor indirect comparisons, the values represent the difference between TBZ and DEU in the mean change in score. Here, positive values are in favor of DEU, and negative values are in favor of TBZ. In the TBZ study, UHDRS chorea scores were adjusted to baseline values and site, and depression was summarized using the Hedges g effect size from the Hamilton Depression Scale. In the DEU study, UHDRS chorea scores were adjusted to baseline values only, and depression was summarized using the Hedges g effect size from the Hospital and Anxiety Depression Scale depression subscale.

^cSignificantly favors TBZ.

^dSignificantly favors DEU.

^eSignificantly favors placebo.